Dynamic regulatory assessments (DRAs), a concept that is linked to rolling marketing authorization application reviews, enable pharmaceutical companies to build their dossiers progressively and submit evidence to regulators as it is generated.
According to Gilead’s EU regulatory policy lead, Nasir Hussain, this way of working could be useful for “all applications,” but...








